Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555003 | 1.00 | POLB (0.37) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL4794959 | 1.00 | POLB (0.37) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL3555806 | 0.89 | KMT2A (0.35) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL5907442 | 0.80 | NPC1 (0.34) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL3658722 | 0.80 | PRMT5 (0.33) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL2928562 | 0.80 | PLCG1 (0.34) | POLBSMN1; SMN2NPC1KMT2AHTT | |
| SCHEMBL3548893 | 0.79 | POLB (0.32) | POLBSMN1; SMN2NPC1KMT2AHTT | |
| SCHEMBL5907432 | 0.79 | NPC1 (0.38) | POLBSMN1; SMN2NPC1KMT2ARAB9A | |
| SCHEMBL5923132 | 0.79 | POLB (0.32) | POLBSMN1; SMN2PLCG1 | |
| SCHEMBL3555646 | 0.79 | NPC1 (0.33) | POLBSMN1; SMN2NPC1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812014-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-18 | — | — | US | disclosed |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | POLB 338/4885SMN1; SMN2 1450/4885NPC1 800/4885 |
| US-20060276445-A1 | Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, MGAM, PGLS | POLB 886/4885SMN1; SMN2 3690/4885NPC1 2612/4885 |
| US-20060217361-A1 | Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, BPGM, B2M | POLB 376/4885SMN1; SMN2 2073/4885NPC1 1707/4885 |
| US-20080312203-A1 | Bicyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, PEPD, B2M | POLB 329/4885SMN1; SMN2 3122/4885NPC1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.